Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib and Omalizumab in Chronic Spontaneous Urticaria
NCT07816328Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of remibrutinib in chronic spontaneous urticaria (CSU) (2 arms), sponsored by Novartis. Primary endpoint: Proportion of participants achieving Urticaria Activity Score over 7 days <=6 at 24 weeks. Started Sep 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07816328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816328.